Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $50.94 USD
Change Today -0.64 / -1.24%
Volume 519.3K
ALR On Other Exchanges
New York
As of 8:04 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

alere inc (ALR) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/29/15 - $51.98
52 Week Low
08/4/14 - $33.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALERE INC (ALR)

alere inc (ALR) Related Businessweek News

View More BusinessWeek News

alere inc (ALR) Details

Alere Inc. provides point-of-care diagnostics and services for infectious and cardiometabolic diseases, and toxicology and in the United States and internationally. It operates in three segments: Professional Diagnostics, Patient Self-Testing, and Consumer Diagnostics. The Professional Diagnostics segment provides diagnostic test products and other in vitro diagnostic tests to medical professionals and laboratories for detection of diseases and conditions in the areas of viral hepatitis; respiratory syncytial virus; influenza; pneumonia; tuberculosis; human immunodeficiency virus/acquired immunodeficiency syndrome; gastrointestinal disease; vector-borne diseases, such as malaria and dengue; and herpes and other sexually-transmitted diseases, as well as diabetes, high blood pressure, high cholesterol, metabolic syndrome, coronary artery disease, heart attack, and heart failure and stroke. The Patient-Self Testing segment provides home monitoring patient self-testing services that support anticoagulation management through frequent self-testing by patients who take warfarin to control their risk for stroke and clotting disorders. The Consumer Diagnostics segment provides products for over-the-counter pregnancy and fertility/ovulation test markets; and over-the-counter drug tests for at-home testing and cholesterol monitoring under the First Check brand name, as well as vaginal gel for the treatment of bacterial vaginosis without antibiotics. Alere Inc. markets its professional diagnostic products to hospitals, reference laboratories, physician offices, and other point-of-care settings through its sales force and distribution networks; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

9,800 Employees
Last Reported Date: 05/28/15
Founded in 1981

alere inc (ALR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $882.1K
Global President of Toxicology
Total Annual Compensation: $650.0K
Global President of Cardiometabolic Business ...
Total Annual Compensation: $548.1K
Global President of Infectious Disease Busine...
Total Annual Compensation: $486.3K
Executive officer
Total Annual Compensation: $425.1K
Compensation as of Fiscal Year 2014.

alere inc (ALR) Key Developments

Alere Inc. Receives NYSE Notice Regarding Late Form 10-Q Filing

Alere Inc. announced that, as a result of its failure to timely file its Quarterly Report on Form 10-Q for the three months ended March 31, 2015 (the “Form 10-Q”), it has received a notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual. The reason for the delay relates to Company’s need to restate its financial statements and other financial data for 2014, as announced by the Company on May 5, 2015, and to file the restated 2014 financial statements prior to filing the Form 10-Q. The Company currently anticipates that it will file the necessary restatements and the Form 10-Q in the near future. The NYSE informed the Company that, under the NYSE’s rules, the Company will have six months from May 18, 2015 to file the Form 10-Q with the SEC. The Company can regain compliance with the NYSE listing standards before that date by filing the Form 10-Q with the SEC.

Alere Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 04:00 PM

Alere Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 04:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Alere Inc. announced delayed 10-Q filing

On 05/12/2015, Alere Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALR:US $50.94 USD -0.64

ALR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $143.93 USD -0.44
BioMerieux €103.70 EUR +0.15
MEDNAX Inc $70.21 USD -0.97
PerkinElmer Inc $52.57 USD -0.16
STERIS Corp $67.46 USD +0.63
View Industry Companies

Industry Analysis


Industry Average

Valuation ALR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 3.0x
Price/Cash Flow 24.8x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at